

DR. JOSEF STEINER
KREBSSTIFTUNG

DR. JOSEF STEINER
KREBSFORSCHUNGSPREIS 2019

**DR. JOSEF STEINER
KREBSFORSCHUNGSPREIS 2019**

Der Dr. Josef Steiner Krebsforschungspreis 2019
geht an Frau Prof. Dr. Serena Nik-Zainal.

Frau Nik-Zainal ist CRUK Advanced Clinician Scientist am Departement für
Medizinische Genetik der Universität Cambridge, England.
Die Preissumme beträgt gesamthaft CHF 1'000'000.

Dr. Josef Steiner Krebsforschungspreis 2019

Doktor Josef Steiner, Inhaber der „Dr. Steiner Apotheke und Bahnhofdrogerie“ in Biel, hat bei seinem Tode im Jahre 1983 ein grosses Vermögen hinterlassen, welches entsprechend seinem letzten Willen die finanzielle Basis der Dr. Josef Steiner Krebsstiftung bildete. Ziel der Stiftung ist die Förderung der Krebsforschung und die Auszeichnung hochverdienter Wissenschaftler auf allen Gebieten der Krebsforschung. Als erster Preisträger konnte 1986 ein Schweizer, Dr. Peter Cerrutti, geehrt werden. Seither konnten zahlreiche hervorragende Wissenschaftler aus Europa, USA, Australien und der Schweiz mit dem Dr. Josef Steiner Preis ausgezeichnet werden.

Im Bestreben, die Krebsforschung im Sinne des Stifters effizient und nachhaltig zu fördern, wird seit 1998 ein hervorragendes Forschungsprojekt für die Periode von vier Jahren mit einem Betrag von 1'000'000 Schweizerfranken unterstützt. Der Forschungsgruppenleiter oder die Forschungsgruppenleiterin wird zusätzlich mit einem persönlichen Preis in der Höhe von 50'000 Schweizerfranken ausgezeichnet.

Die Auswahl des preisgekrönten Projektes erfolgte nach einem mehrstufigen strengen Auswahlverfahren. Der Dr. Josef Steiner Preis 2019 wurde in renommierten Wissenschaftszeitschriften ausgeschrieben. Die eingereichten Projektskizzen wurden vom Stiftungsrat und einer aus Fachvertretern zusammengesetzten Preiskommission gesichtet und bewertet. Als Kriterien wurden die wissenschaftliche Qualität und die Originalität der Projektskizzen, die Qualifikation der Projektverfasser, sowie die Beurteilung der Machbarkeit der vorgeschlagenen Projekte in Betracht gezogen. Sechs hervorragende Projektskizzen wurden ausgewählt und die Verfasserinnen und Verfasser aufgefordert, ein überarbeitetes und detailliertes Projekt einzureichen. Für die Projekte wurden 2 vergleichende Beurteilungen von externen Gutachtern eingeholt.

Zusätzlich wurden die sechs Projektverfassenden zu einem Symposium eingeladen, welches im Januar 2019 an der Universität Bern stattgefunden hat. Anlässlich dieses Symposiums konnten die Forscherinnen und Forscher ihre Projekte vorstellen. Aus diesem strengen Auswahlverfahren ist Fr. Prof. Dr. Serena Nik-Zainal als Siegerin hervorgegangen.

Laudatio für Frau Prof. Dr. Serena Nik-Zainal

Die Dr. Josef Steiner Stiftung verleiht den Josef Steiner Krebsforschungspreis an Frau Prof. Dr. Serena Nik-Zainal in Anerkennung ihrer bahnbrechenden Forschung im Bereich der Entwicklung neuer Methoden der Bioinformatik zur klinisch-relevanten Klassifizierung von Tumoren. Unter Berücksichtigung der Tatsache, dass jedes Genom einer Krebserkrankung eine unterschiedliche und eigene Signatur an Treiber- und Passagiermutationen aufweist, hat sie die herausfordernde Aufgabe auf sich genommen, diese Mutationen in einer grossen Zahl von Tumoren auf ihre Häufigkeit und Verteilung zu untersuchen, angefangen mit der Verteilung somatischer Mutationen in einer grossen Brustkrebspopulation. Dank der Entwicklung und Anwendung innovativer bioinformatischer Rechensysteme konnte sie genetische Gemeinsamkeiten in den verschiedenen Tumoren nachweisen, die potentiell zur Definition von gezielt therapierbaren Entitäten führt.

Curriculum Vitae von Serena Nik-Zainal



CRUK Advanced Clinician Scientist
Honorary Consultant in Clinical Genetics
Group Leader Physiology of Mutagenesis Laboratory
University of Cambridge, UK

Phone: +44 1223 763334
email: snz@mrc-cu.cam.ac.uk
website: <https://www.mrc-cu.cam.ac.uk/research/serenanikzainal>

DR. JOSEF STEINER

KREBSSTIFTUNG

Actual Positions

- 2004 Specialist Registrar in Clinical Genetics**
East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust
- 2009 Wellcome Clinical Research Training Fellow**
Wellcome Sanger Institute
- 2013 Honorary Consultant in Clinical Genetics**
East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust
- 2014 Career Development Fellow Group Leader**
Wellcome Sanger Institute
- 2017 Group leader & CRUK Advanced Clinician Scientist**
MRC Cancer Unit & Department of Medical Genetics
University of Cambridge

Education

- 2013 Certificate of Specialist Registration in Clinical Genetics, East Anglia UK**
- 2012 PhD degree in Cancer Genomics, Wellcome Sanger Institute**
- 2003 MRCP Member of the Royal College of Physicians (London)**
- 2000 MBBChir in Clinical Medicine, University of Cambridge**
- 1998 BA (First Class Honours) in Medical and Veterinary Science Tripos, University of Cambridge**

Postdoctoral Training

2012-2014 Wellcome Sanger Institute

Fellowships, Grants and Awards

- 2019 Basser Gray Grant
- 2019 Dr. Josef Steiner Cancer Research Foundation Award
- 2018 Early Detection Project Grant
- 2017 CRUK Advanced Clinician Scientist Award
- 2017 CRUK Grand Challenge: PRECISION Grant
- 2016 CRUK Pioneer Award
- 2014 William Bate Hardy Prize
- 2014 CRUK Future Leaders Prize
- 2013 Wellcome Beit Prize
- 2013 AACR Scholar-In-Training Prize
- 2013 Wellcome Intermediate Clinical Fellowship
- 2012 EACR Susan G. Komen Prize
- 2012 Robin Winter Prize
- 2009 Wellcome Clinical Research Training Fellowship

Publications

Full bibliography can be found at:

<https://www.ncbi.nlm.nih.gov/myncbi/18oRIWoW3TTkj/bibliography/public/>

Top 20 publications:

1. Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, Gomez C, Degasperi A, Harris R, Jackson SP, Arlt VM, Phillips DH, **Nik-Zainal S**. A Compendium of Mutational Signatures of Environmental Agents. *Cell*. 2019 May 2;177(4):821-836.e16.
2. Brinkman AB, **Nik-Zainal S**, Simmer F, Rodríguez-González FG, Smid M, Alexandrov LB, Butler A, Martin S, Davies H, Glodzik D, Zou X, Ramakrishna M, Staaf J, Ringnér M, Sieuwerts A, Ferrari A, Morganella S, Fleischer T, Kristensen V, Gut M, van de Vijver MJ, Børresen-Dale AL, Richardson AL, Thomas G, Gut IG, Martens JWM, Foekens JA, Stratton MR, Stunnenberg HG. Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. *Nature Communications*. 2019 Apr 15;10(1):1749.
3. Georgakopoulos-Soares I, Morganella S, Jain N, Hemberg M, **Nik-Zainal S**. Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis. *Genome Research*. 2018 Sep;28(9):1264-1271.
4. Zou X, Owusu M, Harris R, Jackson SP, Loizou JI, **Nik-Zainal S**. Validating the concept of mutational signatures with isogenic cell models. *Nature Communications*. 2018 May 1;9(1):1744.
5. **Nik-Zainal S**. The duty to speak up. *Nature Cell Biology*. 2018 Sep;20(9):1006. doi: 10.1038/s41556-018-0171-7. PubMed PMID: 30154558; PubMed Central PMCID: PMC6155444.
6. Garaycochea JI, Crossan GP, Langevin F, Mulderrig L, Louzada S, Yang F, Guilbaud G, Park N, Roerink S, **Nik-Zainal S**, Stratton MR, Patel KJ. Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells. *Nature*. 2018 Jan 11;553(7687):171-177.
7. Zou X, Morganella S, Glodzik D, Davies H, Li Y, Stratton MR, **Nik-Zainal S**. Short inverted repeats contribute to localized mutability in human somatic cells. *Nucleic Acids Research*. 2017 Nov 2;45(19):11213-11221.
8. Drost J, van Boxtel R, Blokzijl F, Mizutani T, Sasaki N, Sasselli V, de Ligt J, Behjati S, Grolleman JE, van Wezel T, **Nik-Zainal S**, Kuiper RP, Cuppen E, Clevers H. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. *Science*. 2017 Oct 13;358(6360):234-238. d
9. Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL, Børresen-Dale AL, Thompson A, Eyfjord JE, Kong G, Stratton MR, **Nik-Zainal S**. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. *Cancer Research*. 2017 Sep 15;77(18):4755-4762.
10. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, **Nik-Zainal S**. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nature Medicine*. 2017 Apr;23(4):517-525.
11. **Nik-Zainal S**, Morganella S. Mutational Signatures in Breast Cancer: The Problem at the DNA Level. *Clinical Cancer Research*. 2017 Jun 1;23(11):2617-2629.
12. Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR, **Nik-Zainal S**. A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. *Nature Genetics*. 2017 Mar;49(3):341-348.
13. **Nik-Zainal S**, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC,

- Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*. 2016 Jun 2;534(7605):47-54.
14. Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, **Nik-Zainal S**. The topography of mutational processes in breast cancer genomes. *Nature Communications*. 2016 May 2;7:11383.
 15. Helleday T, Eshtad S, **Nik-Zainal S**. Mechanisms underlying mutational signatures in human cancers. *Nature Review Genetics*. 2014 Sep;15(9):585-98.
 16. **Nik-Zainal S**, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ, Stratton MR. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. *Nature Genetics*. 2014 May;46(5):487-91.
 17. Alexandrov LB, **Nik-Zainal S**, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilcic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. *Nature*. 2013 Aug 22;500(7463):415-21.
 18. Taylor BJ, **Nik-Zainal S**, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. *Elife*. 2013 Apr 16;2:e00534.
 19. **Nik-Zainal S**, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jönsson G, Garber JE, Silver D, Miron P, Fatima A, Boyault S, Langerød A, Tutt A, Martens JW, Aparicio SA, Borg Å, Salomon AV, Thomas G, Børresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR. Mutational processes molding the genomes of 21 breast cancers. *Cell*. 2012 May 25;149(5):979-93.
 20. **Nik-Zainal S**, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SA, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, Børresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ. The life history of 21 breast cancers. *Cell*. 2012 May 25;149(5):994-1007.

Prof. Dr. Nik-Zainal beschreibt ihr preisgekröntes Projekt wie folgt:

Accelerating holistic cancer genome interpretation towards the clinic

Today, we can read the entire human genome comprising over 3,000,000,000 DNA base pairs in a single experiment, in less than one day, for less than one thousand US dollars. The speed and scale of reading the genome (or sequencing) has increased extraordinarily in less than a decade. The rate-limiting step in using genomic data today is not sequencing - it is the expertise in the analysis of this deluge of data and in making clinically-useful interpretations for the general population.

Early in my research career, we showed that using all of the mutations present in whole genome sequenced (WGS) tumours could reveal *mutational signatures*, imprints left by mutagenic DNA damage and repair processes that have occurred through cancer development^{1,2,3}. Subsequently, we focused on validating these mutation patterns in experimental cellular model systems^{4,5,6}. This powerful combination of computational analytics and experimental insights helped to drive the development of clinical computational tools to interpret whole cancer genome data more effectively.

Every tumor is individual. No two cancer genomes have the same set of mutations that are causally implicated in carcinogenesis (called drivers) or passenger mutations that create mutational signatures⁷. At first glance, it may seem a formidable task to dissect this complexity for clinical applications. However, thanks to the principle of not simply doing an experiment and generating data once, but adding, instead, subsequent datasets and performing computational exploration recurrently thus learning and re-learning from available cancer sequencing data, my team has shown that by taking a holistic approach, it is possible to find commonalities across tumors and interpret the whole picture of cancer genomes for the clinical benefit. In this context, we have pioneered the development of bioinformatic tools to classify tumors in clinically-informative ways, for potentially targetable abnormalities⁸.

To give an example, we developed an algorithm called HRDetect⁸. Machine-learning methods were used to identify critical mutational signatures that defined tumors which were deficient in a critical repair pathway called Homologous Recombination Repair (HR). We applied HRDetect on a cohort of 560 WGS breast cancers. A surprising 22% of tumors were found to show HR-deficiency. This means that ~ 1 in 5 breast cancer patients has a tumor that could be sensitive to selective therapeutics designed for patients that carry inherited *BRCA1/BRCA2* mutation, like poly-ADP ribose polymerase (PARP) inhibitors, and other selective chemotherapeutics such as platinum-based drugs. To translate our research work into clinical application, we are obliged to demonstrate that individual bioinformatic assays such as HRDetect, have prognostic/predictive capabilities. We have indeed done so recently by applying our WGS analysis and interpretation expertise to informative cohorts in a step-wise fashion: first, in small retrospective series⁸, second in larger population-wide studies where excellent treatment and clinical outcome data are available (e.g. South of Sweden study (SCAN-B) manuscript in press), and third, in partnership with pharmaceutical companies to demonstrate performance in clinical trials (manuscript in review). The example of how we developed HRDetect from available data and then rapidly applied it demonstrates the impact of the approach.

In the Clinical School at the University of Cambridge, we further enhance translation of our expertise, develop novel, clinically-meaningful algorithms, and share our knowledge through web-based resources. In this context, the Dr. Josef Steiner Award will help to consolidate our current knowledge into infrastructure that is appropriate for the future. We are building a highly-organised data infrastructure based on an improved automated foundation that will permit learning and relearning from ever-growing datasets. The system is also being built with the intention of making genomic data more accessible and user-friendly for biologists and clinicians that are not computational experts, so that the next generation of researchers may be able to explore these data more efficiently. As scientists and clinicians, big data are only useful if we can extract relevant biological/clinical questions from that data. Thus, a strong processing base coupled to improved organization of curated data will prove to be a set-up that is more suitable for advanced data analytics. We will be able to focus on asking novel biological and clinical questions of these large datasets and ultimately, make clinically-relevant progress. Thanks to the help from the Steiner Foundation, we have already been able to accelerate the development of one of our web-based tools, called Signal⁹ which serves as a reference resource of mutational signatures. This resource has the largest collection of human mutational signatures derived from cancers and from experimental systems. Users are able to explore data down to the individual patient level. Users are also able to perform their own analyses on our website, by uploading their data and then learning what is in their patient/tumor/experimental datasets.

The Steiner Award will be essential for providing the necessary support for developing a novel data infrastructure for advanced analytics in the Physiology of Mutagenesis Laboratory, thereby allowing us to understand mechanisms of mutagenesis, to develop new clinical algorithms, and to build the model for interpreting whole cancer genomes for the benefit of patients in the future.

References

1. **Nik-Zainal S**, et al. Mutational processes molding the genomes of 21 breast cancers. *Cell*. 2012 May 25;149(5):979-93. doi: 10.1016/j.cell.2012.04.024. Epub 2012 May 17. PubMed PMID: 22608084; PubMed Central PMCID: PMC3414841.
2. **Nik-Zainal S**, et al. The life history of 21 breast cancers. *Cell*. 2012 May 25;149(5):994-1007. doi: 10.1016/j.cell.2012.04.023. Epub 2012 May 17. PubMed PMID: 22608083; PubMed Central PMCID: PMC3428864.
3. Alexandrov LB, **Nik-Zainal S** et al. Signatures of mutational processes in human cancer. *Nature*. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. PubMed PMID: 23945592; PubMed Central PMCID: PMC3776390.
4. Taylor BJ, **Nik-Zainal S**, et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. *Elife*. 2013 Apr 16;2:e00534. doi: 10.7554/eLife.00534. PubMed PMID: 23599896; PubMed Central PMCID: PMC3628087.
5. Zou X et al. & **Nik-Zainal S**. Validating the concept of mutational signatures with isogenic cell models. *Nature Communications*. 2018 May 1;9(1):1744. doi: 10.1038/s41467-018-04052-8. PubMed PMID: 29717121; PubMed Central PMCID: PMC5931590.
6. Kucab JE, Zou X, et al & **Nik-Zainal S**. A Compendium of Mutational Signatures of Environmental Agents. *Cell*. 2019 May 2;177(4):821-836.e16. doi: 10.1016/j.cell.2019.03.001. Epub 2019 Apr 11. PubMed PMID: 30982602; PubMed Central PMCID: PMC6506336.
7. **Nik-Zainal S**, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature*. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. PubMed PMID: 27135926; PubMed Central PMCID: PMC4910866.
8. Davies H, et al & **Nik-Zainal S**. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nature Medicine*. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13. PubMed PMID: 28288110; PubMed Central PMCID: PMC5833945.
9. <https://signal.mutationalsignatures.com>




Figure 1: Mutational signatures and whole genome profiles of human cancers: (A) Somatic mutational-signatures can be the outcome of multiple mutational processes. Each mutational process may incur “direct” DNA damage (e.g. UV light causing pyrimidine modifications or DNA repair defects) or “indirect” assaults (e.g. secondary to a disturbance in cellular physiology) and leave a characteristic imprint – or mutational signature – on the cancer genome. The arrows indicate the duration and intensity of exposure to a specific mutational process. The final mutational portrait is a composite of all the mutational processes that have been active over the lifetime of the cancer patient. **(B)** In previous work, we have shown our ability to use machine learning methods to ascertain the multiple mutational-signatures that define tumors with DNA repair deficiencies (first and second circos plots respectively; HR= homologous recombination, MMR = mismatch repair) and tumors with marked abnormalities of cellular physiology (third circos plot) resulting in characteristic appearances. These images are intended to demonstrate the marked differences between tumors with abnormal biologies. Outermost ring = chromosomal ideogram clockwise chr1-chr22,X,Y. Subsequent circles heading inwards: substitutions as dots plotted on log scale of intermutation distance, small insertions/deletions, copy number (pink=losses, green=gains), rearrangements = lines (green=tandem duplications, pink=large deletions, blue=inversions, purple=translocations).